[Skip to Navigation]
Comment & Response
December 2017

ADS-5102 (Amantadine) Extended Release for Levodopa-Induced Dyskinesia

Author Affiliations
  • 1University of Kansas Medical Center, Kansas City
  • 2University of South Florida, Tampa
JAMA Neurol. 2017;74(12):1507-1508. doi:10.1001/jamaneurol.2017.3205

To the Editor We read with interest the Editorial by Wagle Shukla1 regarding our article.2 As discussed in the Editorial, there is a significant unmet need in the treatment of levodopa-induced dyskinesia (LID). It also highlights the benefits of ADS-5102 (amantadine) in the treatment of LID as well as some limitations of the EASE LID Study, which was the first study to demonstrate an oral treatment that reduced both LID and OFF time in Parkinson disease.2 We would like to clarify the following aspects.